Argyle Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Argyle Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.44M	Sell	19,064 -1,648	-8%	-$206K	1.75%	11
2025 Q4	$2.53M	Sell	20,712 -3,327	-14%	-$381K	1.84%	10
2025 Q3	$2.41M	Sell	24,039 -1,845	-7%	-$166K	1.73%	10
2025 Q2	$2.15M	Sell	25,884 -1,081	-4%	-$86.2K	1.77%	9
2025 Q1	$2.19M	Buy	26,965 +4,582	+20%	+$410K	1.87%	9
2024 Q4	$2.02M	Buy	+22,383	New	+$2.17M	1.73%	9

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Argyle Capital Partners's XBI Position: Q1 2026 in Review

Argyle Capital Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 8% in Q1 2026, selling an estimated $206K and leaving 19,064 shares worth $2.44M. The position accounts for 1.75% of the portfolio, ranked #11.

Argyle Capital Partners first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.53M in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Argyle Capital Partners held 19,064 shares of State Street SPDR S&P Biotech ETF worth $2.44M as of Q1 2026.
Argyle Capital Partners sold 1,648 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $206K.
State Street SPDR S&P Biotech ETF made up 1.75% of Argyle Capital Partners's portfolio in Q1 2026, its #11 holding.
Argyle Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
Argyle Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $2.53M in Q4 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Argyle Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.